Viewing data from:

PROSTASCINT

BLA

CAPROMAB PENDETIDE | B103608 | CYTOGEN

1 product0 Purple Book patents

Biologic LOENo LOE data

No exclusivity dates or listed patents found in Purple Book

Purple Book Patents

No listed patents in Purple Book.

Estimated Patent LOE

Feb. 16, 20436072 days remaining

Based on latest discovered patent 11583544(formulation) · relevance 55/100

Estimate based on AI-discovered patents. No patents are officially listed in the Purple Book for this product.

Discovered Patents

View all 5 patents →

5 AI-discovered patents, sorted by relevance.

Composition

(3)

95/1008632777Grant: 2014-01-21 | Exp: 2034-01-16

88/1008198416Grant: 2012-06-12 | Exp: 2032-06-07

88/1009238694Grant: 2016-01-19 | Exp: 2036-01-14

Formulation

(2)

55/10011583544Grant: 2023-02-21 | Exp: 2043-02-16

55/100OB10166184Grant: 2019-01-01 | Exp: 2038-12-27

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

Purple Book (Biologics)

BLA 103608

351(a) ReferenceLicensedCDERInjection

Proper Name

capromab pendetide

Applicant

Aytu BioScience, Inc.

Approval Date

28-Oct-96

Source: FDA Purple Book (purplebooksearch.fda.gov).

Approval Letters

2 letters from Drugs@FDA

Date	Submission	Document
Jun 27, 2012	SUPPL -5043	View Letter (PDF)
Mar 26, 2004	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — 05.MG/ML

▴

VIAL; INTRAVENOUS | Approved: 1996-10-28 00:00:00

No patent or exclusivity listings for this strength.